Status:
ENROLLING_BY_INVITATION
Real-World Assessment of Therapeutic Strategies and Survival Outcomes Following First-Line Tislelizumab Therapy in Advanced Non-Small Cell Lung Cancer
Lead Sponsor:
Shanghai Chest Hospital
Conditions:
Non-Small-Cell Lung Cancer
Non-Small-Cell Lung Cancer Stage IV
Eligibility:
All Genders
Brief Summary
This study is an observational study evaluating the treatment patterns and clinical outcomes after progression on first-line Tislelizumab treatment in advanced NSCLC. Based on the inclusion and exclus...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed unresectable locally advanced or metastatic NSCLC based on the 8th edition of the AJCC staging system.
- Previously received first-line treatment with Tislelizumab for advanced NSCLC.
- Medical records of disease progression after first-line treatment.
Exclusion
- Patients with incomplete key baseline and treatment information，including clinical stage, pathological type, treatment regimen, tumor assessment record after treatment ect.
- Patients included in anti-tumor drug intervention or unblinded clinical trials, in which the treatment being administered is unknown.
Key Trial Info
Start Date :
August 16 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06962449
Start Date
August 16 2024
End Date
December 31 2026
Last Update
May 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China, 200030